Answers are grounded in this paper and cite their sources.
T2DM alters immune status and promotes vascular proliferation in breast cancer, suggesting integration of metabolic control may optimize patient management.
T2DM promotes vascular proliferation and suppresses intratumoral immune activity in BC, creating an angiogenic yet immunosuppressed microenvironment. These findings highlight the impact of metabolic imbalance on tumor biology and underscore the need for integrating metabolic control and immunomodulatory strategies in the management of diabetic BC patients.
No takes yet. Share an insight, caveat, or question.
Foca et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: